EDGE MEDICAL-B

Shenzhen Edge Medical opened higher and rose sharply in the morning session, gaining about 5.1% to HKD 38.00 by mid-morning, primarily driven by the company's recent share buybacks boosting sentiment and a board meeting announcement to review interim results, alongside a turnaround to profitability. Q4 2025 revenue surged 146.79% YoY to HKD 170.3 million, with net profit turning positive at HKD 267,000 and a net profit margin of 0.16%, while operating loss narrowed 89.28% YoY. However, the stock remains 48.44% below its 52-week high of HKD 73.70 and trades below both its MA20 (HKD 38.38) and MA60 (HKD 40.62), with a YTD decline of 32.86%, suggesting the earnings recovery is not yet fully priced in.

Shenzhen Edge Medical surged in early afternoon trade, closing at HKD 40.66, up 5.17%, with an intraday swing of ~5.02%; the session low of HKD 38.740 was set in the morning while the high of HKD 40.660 came in the afternoon. The company has disclosed multiple share buybacks, with the latest repurchase price at HKD 36.1, boosting market sentiment. Morgan Stanley reiterated a Buy rating, while DBS also initiated coverage. Revenue surged 146.79% YoY to HKD 170.3 million, but net profit remained thin at HKD 0.27 million, with a net margin of only 0.16%, indicating fundamentals are still in early recovery. Though the stock recovered above the MA20 (HKD 38.516), it remains 44.83% below the 52-week high of HKD 73.7 and down 28.16% YTD. The stock also trades below the MA60 (HKD 42.27), suggesting medium-term weakness persists.

Edge Medical opened higher and rallied in the morning session, reaching HKD 40.0 by 10:19 BJ, up 5.0% from the previous close of HKD 38.08, with an intraday range of HKD 38.1 to 40.0, driven by recent share buybacks (e.g., at HKD 36.1, 34.78, 38.88) and positive analyst sentiment from Morgan Stanley (Buy) and DBS (new rating). Q4 2025 revenue surged 146.79% YoY to HKD 170.3 million, with net profit turning positive at HKD 0.27 million (EPS HKD 0.0007) and operating loss narrowing 89.28% YoY, signaling fundamental improvement. However, the stock remains 45.73% below its 52-week high of HKD 73.7 and trades below the MA60 (HKD 43.062), with a YTD decline of 29.33% and a PB of 11.76x, reflecting the early stage of earnings recovery.

Edge Medical surged in the afternoon session, closing at HKD 40.30, up 5.66% from the previous close of HKD 38.14, hitting the day's high. The intraday pattern was a 'rebound from lows': it opened at HKD 38.96 in the morning, dipped to HKD 38.14, then recovered to HKD 39.56; after the afternoon session started, it continued to rise, accelerating to HKD 40.30 by the close. Total volume was 146,400 shares with turnover of about HKD 5.78 million. The rally was driven by positive market reaction to the company's ongoing share buybacks and institutional confidence. Recent disclosures include a buyback at HKD 36.1 per share and a cancellation of repurchased shares. Morgan Stanley maintained a 'Buy' rating, DBS initiated coverage, and Guotai Haitong reiterated a 'Buy' rating. Financially, Q4 2025 operating revenue was approximately HKD 170.33 million, up 146.79% YoY, with net profit of HKD 266,887, turning profitable, though operating profit remained negative at HKD -7.49 million, narrowing 89.28% YoY. However, the stock is still 45.32% below its 52-week high of HKD 73.70 and trades below its 60-day MA of HKD 44.79, with a YTD decline of 28.8%. The P/B ratio of 11.86x and negative P/E reflect high growth expectations, while sustainability of profitability and capital support remain key watchpoints.

Shenzhen Edge Medical opened lower and declined in the morning session, hitting an intraday low of 36.820 HKD before closing at 36.960 HKD, down 4.89% from the previous close of 38.860 HKD, after briefly rising to 40.360 HKD at the open, forming a pattern of opening high and then falling. The company's recent share repurchases, including a July 17 disclosure of buyback at 36.1 HKD each and prior repurchases between 34.78 and 38.88 HKD in June, provided initial support for the stock. However, the stock remains 49.85% below its 52-week high of 73.7 HKD, trades below both the 20-day MA (38.994 HKD) and 60-day MA (44.968 HKD), and has fallen 34.7% year-to-date, reflecting persistent market concerns about the commercialization pace of surgical robots. The latest earnings showed Q4 revenue surged 146.79% YoY to 170.33 million HKD, with net profit turning positive to 266,887 HKD, though the net profit margin remained at only 0.16%, indicating fundamental improvement still needs time to materialize.